R. Teng

Statistics

Publications

Citations

466

H-Index

Active since

2009

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Catholic University of Korea

R. Teng is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, diabetes mellitus, and clinical pharmacology.

Publications per year

2009–2021

Publications

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

Debora Williams‐Herman, J. Johnson, R. Teng et al. · Diabetes Obesity and Metabolism · 2010 · 153 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

Debora Williams‐Herman, Jeremy Johnson, R. Teng et al. · Current Medical Research and Opinion · 2009 · 127 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes

Kun‐Ho Yoon, Gerald Shockey, R. Teng et al. · International Journal of Clinical Practice · 2011 · 51 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of initial combination therapy with sitagliptin and metformin on <i>β</i> ‐cell function in patients with type 2 diabetes

Debora Williams‐Herman, Lei Xu, R. Teng et al. · Diabetes Obesity and Metabolism · 2011 · 39 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone—a factorial study

Robert R. Henry, Bart Staels, Vivian Fonseca et al. · Diabetes Obesity and Metabolism · 2013 · 36 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

1–5 of 7